Hepatitis D Clinical Trial
Official title:
Registry-based Study in Patients With Hepatitis D Virus (HDV) Infection in China
This is a retrospective, prospective, noninterventive, multicenter registry study. Patients diagnosed with HDV infection (based on positive HDV RNA) were included in this study and were followed up for at least 5 years to evaluate their disease progression and clinical outcomes (including death, liver transplantation, hepatocellular carcinoma [hcc], liver decompensation, and cirrhosis) during the 5-year follow-up period. All patients were followed up at least once a year after they were included in the study. It was in 2016 HDV infection first reported in China. Since January 1, 2016, all patients diagnosed with HDV infection can be enrolled in this study and evidence confirming the diagnosis (including but not limited to HDV RNA test reports and medical records, etc.) must be delivered. The main test results (including serum HDV RNA, ALT, and tests to determine the presence of liver cirrhosis, decompensation of liver function, and liver cancer such as B-ultrasound and FibroScan) of these patients each year from diagnosis to enrollment should be collected and filled in the case report form (CRF). Follow-up data of patients with serum anti-HDV positive and HDV RNA negative can be recorded and followed up on this platform, with informed consent of the patients is required. Patients whose serum HBV RNA turn positive during the follow-up period will be included in the follow-up cohort of the study.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02044055 -
Mother-to-child Hepatitis D Transmission
|
N/A | |
Completed |
NCT02375906 -
The Hepatitis Delta International Network
|
||
Not yet recruiting |
NCT05394623 -
Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study)
|
||
Recruiting |
NCT04863703 -
Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)
|
||
Recruiting |
NCT06397859 -
Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
|
||
Recruiting |
NCT00001971 -
Evaluation of Patients With Liver Disease
|
||
Recruiting |
NCT06264583 -
HDV-Europe: Prevalence and Outcome of HDV in HIV/HBV Coinfection
|
||
Recruiting |
NCT05928000 -
HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV
|
||
Recruiting |
NCT06122285 -
Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)
|
||
Terminated |
NCT04847440 -
A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection
|
Phase 2 | |
Recruiting |
NCT05936073 -
DELTA DESCRIBE: the French Collaborative Project
|
||
Completed |
NCT00932971 -
HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis
|
Phase 2 | |
Completed |
NCT06360484 -
Prevalence and Clinical Characterization of Hepatitis D Virus (HDV) Infection Among Sudanese Patients With Hepatitis B Virus
|
||
Completed |
NCT02511431 -
Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
|
Phase 2 | |
Recruiting |
NCT05903742 -
Standardising Care for Hepatitis Delta in the Netherlands
|
||
Not yet recruiting |
NCT03362866 -
Epidemiology of Hepatitis B, C and Delta in Reunion Island
|
||
Terminated |
NCT01316185 -
Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)
|
Phase 1 | |
Recruiting |
NCT05264272 -
Disease Loads and Status of Treatment
|
||
Completed |
NCT05002907 -
Epidemiology of Hepatitis B, C and D and HIV Along the Maroni River Bordering French Guiana and Suriname (MaHeVi)
|
||
Not yet recruiting |
NCT05467553 -
A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection
|
Phase 2 |